|
US4999382A
(en)
|
1988-10-26 |
1991-03-12 |
Massachusetts Institute Of Technology |
Compositions for treating tobacco withdrawal symptoms and methods for their use
|
|
US8329217B2
(en)
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
|
US20040102440A1
(en)
|
2002-07-01 |
2004-05-27 |
Wong Erik Ho Fong |
Method of promoting smoking cessation
|
|
WO2005072705A1
(en)
|
2004-01-29 |
2005-08-11 |
Neuromolecular, Inc. |
Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
|
|
WO2005102366A2
(en)
|
2004-04-19 |
2005-11-03 |
Philip Maxwell Satow |
Lithium combinations, and uses related thereto
|
|
US20090054489A1
(en)
|
2005-02-23 |
2009-02-26 |
Prexa Pharmaceuticals, Inc. |
Multimediator Dopamine Transport Inhibitors, and Uses Related Thereto
|
|
CA2598838A1
(en)
|
2005-02-23 |
2006-08-31 |
Prexa Pharmaceuticals, Inc. |
Multimediator 5-ht6 receptor antagonists, and uses related thereto
|
|
EP2258382A3
(en)
|
2005-03-31 |
2014-05-14 |
Amylin Pharmaceuticals, LLC |
Amylin and amylin agonists for treating psychiatric diseases and disorders
|
|
CN101203505A
(zh)
|
2005-04-22 |
2008-06-18 |
惠氏公司 |
苯并二氢吡喃和苯并吡喃衍生物及其用途
|
|
MX2007012882A
(es)
|
2005-04-22 |
2007-12-10 |
Wyeth Corp |
Nuevas combinaciones terapeuticas para el tratamiento o prevencion de la depresion.
|
|
KR20080105104A
(ko)
*
|
2006-03-24 |
2008-12-03 |
와이어쓰 |
우울증 치료를 위한 신규한 치료학적 병용제
|
|
CA2648280C
(en)
|
2006-04-03 |
2014-03-11 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
|
CN101657193A
(zh)
*
|
2007-03-09 |
2010-02-24 |
切尔西治疗公司 |
用于治疗纤维肌痛的屈昔多巴及其药物组合物
|
|
EP2514417A3
(en)
*
|
2007-05-07 |
2013-01-30 |
Chelsea Therapeutics, Inc. |
Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
|
|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
WO2011057199A1
(en)
|
2009-11-06 |
2011-05-12 |
Adenios, Inc. |
Compositions for treating cns disorders
|
|
GB201003734D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Delayed prolonged drug delivery
|
|
GB201003731D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Immediate/delayed drug delivery
|
|
WO2011119227A2
(en)
|
2010-03-25 |
2011-09-29 |
Columbia Northwest Pharmaceuticals, Llc |
Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
|
|
PL2560624T3
(pl)
*
|
2010-04-23 |
2019-01-31 |
Kempharm, Inc. |
Formulacja terapeutyczna do zmniejszania skutków ubocznych leku
|
|
US20130324609A1
(en)
|
2010-10-08 |
2013-12-05 |
University Of Utah Research Foundation |
Depression disorder therapeutics with creatine analogs
|
|
US20130217673A1
(en)
|
2012-02-22 |
2013-08-22 |
Warsaw Orthopedic, Inc |
Mixed monoamine reuptake inhibitor in a biodegradable polymer carrier
|
|
PE20141906A1
(es)
*
|
2012-03-12 |
2014-12-05 |
Janssen Pharmaceutica Nv |
Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
|
|
WO2014120936A2
(en)
|
2013-01-30 |
2014-08-07 |
Pharmorx Therapeutics, Inc. |
Treatments for depression and other diseases with a low dose agent
|
|
US10828302B2
(en)
|
2016-03-10 |
2020-11-10 |
Janssen Pharmaceutica Nv |
Methods of treating depression using orexin-2 receptor antagonists
|
|
US10624939B2
(en)
|
2017-05-23 |
2020-04-21 |
Luke Klele |
Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
|
|
US20180338959A1
(en)
|
2017-05-24 |
2018-11-29 |
Ovid Therapeutics Inc. |
Treatment of depressive disorders
|
|
US20200147093A1
(en)
|
2018-10-15 |
2020-05-14 |
Axsome Therapeutics, Inc. |
Use of esreboxetine to treat nervous system disorders such as fibromyalgia
|
|
CN111233737B
(zh)
|
2020-03-16 |
2021-05-11 |
东莞市东阳光新药研发有限公司 |
芳杂环类衍生物的盐及其用途
|